Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × NSCLC × nimotuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Nasopharyngeal Carcinoma 6 Squamous Cell Carcinoma of Head and Neck 4 Esophageal Squamous Cell Carcinoma 4 Uterine Cervical Neoplasms 3 Pancreatic Neoplasms 2 Nasopharyngeal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Cervical Dysplasia 1 Stomach Neoplasms 1 Solid Tumors 1 Solid Tumor 1 Recurrence 1 Oropharyngeal Neoplasms 1 Neoplasms 1 Nasopharyngeal Diseases 1 NSCLC 1 Meningeal Carcinomatosis 1 Lung Neoplasms 1 Hypopharyngeal Neoplasms 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Diffuse Intrinsic Pontine Glioma 1 Carcinoma, Squamous Cell 1 Advanced Colorectal Cancer 1

Interventions

Gefitinib 5 icotinib 4 apatinib 3 anlotinib 3 Pemetrexed 3 Erlotinib Hydrochloride 3 Docetaxel 3 osimertinib 2 dacomitinib 2 camrelizumab 2 aflutinib 2 Thalidomide 2 Drug Therapy 2 Carboplatin 2 Afatinib 2 spartalizumab 1 pembrolizumab 1 nimotuzumab 1 envafolimab 1 Vinorelbine 1 Tyrosine Kinase Inhibitors 1 S 1 (combination) 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Cisplatin 1 Bevacizumab 1 Axitinib 1 Aspirin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01861223 2014-02-25

Afatinib Plus Nimotuzumb for NSCLC

Samsung Medical Center

Phase 1/2 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡